VanEck Biotech ETF
BBH
115 hedge funds and large institutions have $152M invested in VanEck Biotech ETF in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 29 reducing their positions, and 9 closing their positions.
46% more capital inflows, than outflows
Capital inflows: $11.8M | Capital outflows: $8.08M
1.02% more ownership
Funds ownership: 32.93% → 33.94% (+1%)
1% less funds holding
Funds holding: 116 → 115 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
28% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$3.87M |
| 2 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$1.96M |
| 3 |
Goldman Sachs
New York
|
+$1.91M |
| 4 |
Jane Street
New York
|
+$1.19M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$567K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.55M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.43M |
| 3 |
Atlas Capital Advisors
Jackson,
Wyoming
|
-$960K |
| 4 |
Miller Investment Management
West Conshohocken,
Pennsylvania
|
-$745K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$572K |
BBH Hedge Fund Activity: Q3 2024 in Review
115 of the 6,990 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2024, worth a combined $152M — up 7% from $142M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BBH and 8 opened new positions — a net loss of 1 holder — while 29 trimmed existing stakes and 21 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $3.87M. The largest seller was Susquehanna International Group, cutting an estimated $1.55M.
- 115 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2024, down from 116 in Q2 2024.
- Funds reported $152M of VanEck Biotech ETF stock for Q3 2024, up 7% quarter-over-quarter.
- 8 funds opened new VanEck Biotech ETF positions in Q3 2024 and 9 closed out, a net change of -1 holder.
- The largest VanEck Biotech ETF buyer in Q3 2024 was Citadel Advisors, an estimated $3.87M added.
- The largest VanEck Biotech ETF seller in Q3 2024 was Susquehanna International Group, an estimated $1.55M sold.
Based on aggregated 13F filings for Q3 2024.